Interface Biologics was founded by Dr. Paul Santerre, and is based on his groundbreaking work at the University of Toronto on improving the biocompatibility of medical implants. Dr. Santerre investigated the effects of low molecular weight additives in polyurethanes and their ability to migrate to the nano surface of materials, creating a non-reactive surface layer. In the process, he also discovered that the surface chemistry of certain materials could be engineered to respond to signals from the body’s own immune system. Dr. Santerre recognized the medical and commercial impact of his discoveries.
In December 2001, New Generation Biotech Fund provided the initial seed capital, and Interface Biologics was formed. The company has raised a total of $26MM in venture capital, most recently raising $1MM from MaRS Investment Accelerator Fund in 2011. IBI’s current investors are the Business Development Bank of Canada, Covington Capital and the MaRS Investment Accelerator Fund.
In July 2005, Interface Biologics moved into Toronto’s acclaimed MaRS Innovation Centre—a collaborative facility dedicated to accelerating emerging technologies, located near the University of Toronto campus and seven specialty hospitals. Interface Biologics boasts state of the art laboratory facilities and currently employs 20 people with dedicated expertise in biochemistry, pharmacology, engineering, chemistry, microbiology, biology, process manufacturing, marketing, finance and management.
Since its time at MaRS the company has been issued four U.S. Patents with a number of international jurisdictions and has filed twelve patent applications. The company received ISO 13485 certification in 2010 and manufactures its anti-thrombic additives in an ISO 9001 certified facility.
Contact Info
Interface Biologics, Inc.
MaRS Centre, South Tower
101 College Street, Suite 300
Toronto, ON
M5G 1L7
Main Line (416) 673-8170 Fax (416) 977-1329
Tom Reeves of Interface Biologics (IBI) offers his input about the company’s roadmap towards commercialization, as well as IBI’s differentiation and the advantages of collaborating with international partners. You joined…
World Courier’s national operations manager in Canada covers the topics of moving to GxP standards, and the logistics challenges faced by being a logistics company in such a…
Dr. Youssef Benanni, before becoming Site Head and VP of R&D, worked as a Sr. Group leader with Abbott before moving on to being Sr. Director of Medicinal Chemistry with…
Dr. Youssef Benanni, before becoming Site Head and VP of R&D, worked as a Sr. Group leader with Abbott before moving on to being Sr. Director of Medicinal Chemistry with…
Dr. Youssef Benanni, before becoming Site Head and VP of R&D, worked as a Sr. Group leader with Abbott before moving on to being Sr. Director of Medicinal Chemistry with…
Mr. Pierre Laurin is a senior executive with 28 years of experience in the pharmaceutical and biotechnology industry. Involved in the development of ProMetic’s platform technology since 1989, Mr. Laurin…
You have had a wealth of experience in the pharmaceutical industry with different positions in key therapeutic areas, ranging from Argentina, Latin America, Middle East & Africa, Algeria, Switzerland and France.…
You have been managing the Canadian affiliate of Shire since 2004. Could you briefly describe some of the key milestone achievements of this affiliate in the last few years? Shire…
You have been managing the Canadian affiliate of Shire since 2004. Could you briefly describe some of the key milestone achievements of this affiliate in the last few years? Shire…
You have been managing the Canadian affiliate of Shire since 2004. Could you briefly describe some of the key milestone achievements of this affiliate in the last few years? Shire…
With a Master’s Degree in Marketing Science from the University of Leicester and a Degree in Management Information Systems from Université du Québec à Montréal Jacques Dessurealt has had a…
Tell us about the Canada Foundation for Innovation (CFI) – where does Canada fit on the world stage of innovation and how are you ensuring Canada stands out as a…
Dr. Douville talks investment, the company’s role in R&D in Canada and their plans for some of their future products. You founded Milestone Pharmaceuticals in 2005, having founded Galileo Genomics…
See our Cookie Privacy Policy Here
